EGFR [NM_005228.5] Knockout A-549 Cell Line

The EGFR [NM_005228.5] Knockout A-549 Cell Line is a human CRISPR/Cas9-engineered loss-of-function model in which the EGFR gene has been disrupted in the A-549 background, resulting in loss of functional EGFR expression. This stable edited cell line provides an in vitro system for studying the consequences of eliminating a major receptor tyrosine kinase input in a pulmonary epithelial cancer context. As the host line is derived from human lung alveolar epithelial adenocarcinoma, the model is relevant for investigations of epithelial signaling, oncogenic pathway regulation, and growth factor-dependent cellular responses.

A-549 cells are widely used as a human lung adenocarcinoma model with alveolar type II epithelial-like characteristics, including epithelial morphology and surfactant-associated features. In experimental settings, they serve as a barrier-forming respiratory epithelial system for analysis of lung cancer biology, signal transduction, and pharmacologic response. Their pulmonary epithelial context makes them useful for examining how receptor-driven signaling networks regulate proliferation, survival, migration, and stress adaptation in non-small cell lung cancer-relevant cells.

EGFR encodes a transmembrane ERBB family receptor activated by ligands including EGF, TGFA, HBEGF, AREG, BTC, and EREG. Ligand binding promotes receptor dimerization, including heterodimer formation with ERBB2 and ERBB3, followed by autophosphorylation and recruitment of signaling adaptors and effectors such as GRB2, SHC1, SOS1, GAB1, PIK3R1, PLCG1, CBL, and SRC. These proximal events transmit signals to KRAS, BRAF, MAP2K1, MAPK1/MAPK3, PIK3CA, AKT1, MTOR, STAT3, and STAT5A, and influence downstream transcriptional outputs including MYC, CCND1, FOS, JUN, and BCL2L1. EGFR signaling is therefore positioned upstream of the RAS-RAF-MEK-ERK cascade, PI3K-AKT-mTOR signaling, PLCG1-PKC signaling, JAK-STAT activation, and receptor endocytosis and trafficking machinery involving EPS15 and the AP2 complex. These pathways are central to lung adenocarcinoma, glioblastoma, colorectal cancer, head and neck squamous cell carcinoma, and therapeutic resistance to EGFR-targeted agents.

Within A-549 cells, EGFR knockout provides a defined framework for interrogating how loss of receptor-proximal signaling reshapes epithelial growth factor responsiveness and pathway dependence. This is particularly useful for separating EGFR-dependent from compensatory ERBB, MAPK, or PI3K signaling inputs, and for studying effects on epithelial proliferation, migration, and survival programs in a non-small cell lung cancer-relevant background.

This cell line is suitable for western blotting and phospho-signaling analysis of ligand-stimulated pathway activation, including changes in ERK, AKT, PLCG1, or STAT signaling after EGF-family stimulation. It can also be applied in RT-qPCR and RNA-seq studies to define EGFR-regulated transcriptional programs; in immunofluorescence and flow cytometry to assess receptor-associated phenotypes; in proliferation, apoptosis, migration, and invasion assays to quantify functional consequences of receptor loss; and in co-immunoprecipitation, reporter assays, and drug sensitivity studies to examine receptor crosstalk, downstream pathway dependency, and resistance mechanisms relevant to targeted therapy research. Researchers may contact Ascent Research for additional technical information, product details, or related gene-edited cell models.